Normal development of vaccine in timeline:

Current companies with vaccine trials underway:

Development time of previous vaccines:

Approval percentage of drug trials:

Set goal for COVID-19 vaccine"

What if we fail to develop a vaccine:

Please read full article in written by Stuart A. Thompson in The New York Times on April 30-2020